Tg Therapeutics (TGTX) Long-Term Deferred Tax (2025 - 2026)
Tg Therapeutics (TGTX) posted quarterly Long-Term Deferred Tax of $344.1 million for Q1 2026, down 1.11% quarter-over-quarter from $348.0 million in Q4 2025.
Powered by 
Analysis
Tg Therapeutics (TGTX) Long-Term Deferred Tax (2025 - 2026) Analysis & Trends
Tg Therapeutics' Long-Term Deferred Tax history runs 2 years deep, the most recent figure standing at $344.1 million for Q1 2026.
- In Q1 2026, Long-Term Deferred Tax changed N/A year-over-year to $344.1 million; the TTM figure through Mar 2026 stood at $344.1 million (changed N/A YoY), while the FY2025 annual figure was $348.0 million, changed N/A from the prior year.
- Long-Term Deferred Tax for Q1 2026 stood at $344.1 million, down from $348.0 million in the prior quarter.
- The five-year high for Long-Term Deferred Tax was $366.6 million in Q3 2025, with the low at $344.1 million in Q1 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Tg Therapeutics | 7.97 Bn | 7.29 Bn | 199.14 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 343.43 Mn |
| Mar 31, 2026 | 344.14 Mn |
| Dec 31, 2025 | 348.00 Mn |
| Sep 30, 2025 | 366.63 Mn |